FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1675-1676 April 19, 2007 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ross, D. B. PubMed Citation

To the Editor: In response to the article by Ross in this issue of the Journal,¹ we wish to clarify how the Food and Drug Administration (FDA) reviewed Ketek (telithromycin). Although there are other statements or suggestions in the article that also need clarification, we address a few key points in the limited space available here.

First, safety concerns were identified by the FDA early in the review process and taken very seriously throughout four years and three review cycles. The FDA's approval decision followed a careful review of the safety data submitted, including foreign postmarketing adverse-event reports that . . . [Full Text of this Article]

This article has been cited by other articles:

• Bolesta, S., Roslund, B. P. (2008). Elevated hepatic transaminases associated with telithromycin therapy: A case report and literature review. Am J Health Syst Pharm 65: 37-41 [Abstract] [Full Text]